Peter J. Arduini, President and CEO of GE HealthCare, Named Chair of AdvaMed Board of Directors

AdvaMed logo

December 11, 2023 | WASHINGTON, D.C.,  – Today, AdvaMed, the Medtech Association, announced that Peter J. Arduini, president and CEO of GE HealthCare, will become the Chair of the AdvaMed Board of Directors.

“The entire board and the global industry AdvaMed represents are very excited to have Peter as our new Board Chair during this critical time for medtech. Artificial Intelligence, imaging and digital technology represent important areas of innovation that can significantly accelerate diagnosis and improve the personalization of patient care. Peter’s proven record of leadership across more than three decades in medtech and imaging will enable him to advance AdvaMed’s goal of achieving healthier lives and healthier communities around the world. I look forward to working with him,” said AdvaMed President and CEO Scott Whitaker, who also serves as President of the AdvaMed Board of Directors.

Arduini said, “I appreciate the confidence my fellow AdvaMed Board members have placed in me as the Board’s new chair.  Through Scott’s leadership, AdvaMed has become a unifying voice for our industry to foster growth and innovative new solutions for patients, providers and health systems. The medical technology industry is at the forefront of defining the future of healthcare through smart devices, diagnostics and digital solutions that can enable earlier and more precise diagnoses, targeted treatments and improved patient outcomes. We need policies that keep pace with innovation, while fostering the highest ethical standards that improve patient access to the best care possible. With the promise of artificial intelligence and the interconnectivity of medical technologies, there has never been a more important time in our history to make profound and lasting changes in the delivery of care for patients.” 

Arduini has been president and chief executive officer of GE HealthCare, a global medical technology, pharmaceutical diagnostics, and digital solutions innovator, since January 2022.  He previously served as president and chief executive officer of Integra LifeSciences Holdings Corporation, corporate vice president and president of Medication Delivery, Baxter Healthcare, from 2005 to 2010. He previously spent 15 years at GE Healthcare where in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Arduini also serves on the Boards of Directors of GE HealthCare, Bristol Myers Squibb and the National Italian American Foundation.

In the wake of former AdvaMed Chair Ashley McEvoy’s departure from Johnson & Johnson Medtech in October, Arduini stepped in to serve as interim chair over the past several weeks. The full Board elected him unanimously to a two-year term, which began immediately Friday.

Arduini  will unveil his priorities as AdvaMed Chair in early 2024.

Opinion: Georgia's Congressional delegation can lead the way on correcting 'pill penalty'

By Sheran Brown • May 1, 2025
Opinion: Georgia's Congressional delegation can lead the way on correcting 'pill penalty'  Maria Thacker Goethe President and CEO, Georgia Life Sciences: May 1, 2025 EPIC Act offers commonsense fix to 'pill penalty' problem

Study Maps Economic Fallout of NIH Cuts in Georgia

By Maria Thacker Goethe • April 18, 2025
The Science & Community Impacts Mapping Project (SCIMaP) shows how proposed federal funding cuts lead to reduced economic activity and job losses nationwide.

Georgia Life Sciences Selects Fulton County Schools Innovation Academy Student as the 2025 Georgia BioGENEius Winner

By Sheran Brown • April 10, 2025
Georgia Life Sciences Selects Fulton County Schools Innovation Academy Student as the 2025 Georgia BioGENEius Winner Sandy Springs & Rockmart Teens Take Top Honors in Statewide Science Competition Atlanta, GA (April 4, 2025) – Georgia Life Sciences today named Bhavya Alapati , a junior at Fulton County Schools Innovation Academy, as the winner of the 2025 Georgia BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field. Eleven students from across Georgia competed for this year’s title and cash prize. Bhavya’s project investigated a novel method of identifying strokes using a device she created called SpectroStroke, a small-scale spectrophotometer, to detect homocysteine, an amino acid product that is associated with stroke. Bhavya identified the ability of homocysteine to be detected using Ellman’s reagent, which reacts with the free sulfhydryl group on the molecule to produce a yellow color. Bhavya created a wearable patch that contains the Ellman’s reagent. Then, she designed the SpectroStroke to be able to detect the color change when the patch is exposed to elevated levels of homocysteine. Bhavya’s SpectroStroke can detect normal levels of homocysteine up to extremely high levels seen in those experiencing a stroke. The ability to detect a stroke earlier would reduce damage and long-term effects of the condition. A future iteration of the SpectroStroke would include real-time monitoring capabilities to help track changing homocysteine levels. "Supporting and celebrating outstanding research and innovation in biotechnology is vital for the future of science and medicine. The Georgia BioGENEius Challenge not only encourages the brightest young minds to explore their potential but also nurtures the next generation of leaders who will drive groundbreaking advancements in biotechnology,” said Georgia Life Sciences President and CEO Maria Thacker-Goethe. “By recognizing and empowering these students, we are helping to shape a future where innovation thrives and the possibilities for improving lives are endless. Well done, Bhavya!” Georgia Life Sciences also congratulates the Georgia BioGENEius runner-up, Shelby Kendrick , who is a senior at Paulding County High School in Dallas, GA. Shelby’s research investigated the ability of Aspergillus terreus, a fungus found in soil, to degrade pre-treated polypropylene plastic (PP). This fungus has been discovered to produce high concentrations of degrading enzymes and raises the moisture level of its substrate. Shelby isolated the fungus from soil samples and confirmed the species using PCR amplification and DNA barcoding. Samples of polypropylene were pre-treated with 75% ethanol and UV exposure, then placed in a liquid culture of A. terreus in Minimal Salt Medium (MSM) media, and the culture was incubated for 23 days. At the end of the trial period, PP samples were analyzed using Scanning Electron Microscopy. These samples showed changes in their surface layer, indicating evidence of biodegradation. Polypropylene plastic is found in household items such as plastic cups and is a known problem in the environment due to its inability to degrade. Shelby’s future research on the use of A. terreus for biodegradation includes optimizing degradation conditions and assessing methods of application in the environment. Judging the 2025 Georgia BioGENEius Challenge were Ralph L. Cordell, CDC, and Alex Harvey, ViaMune. Cash prizes were awarded to Bhavya and Shelby. # # # About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
MORE POSTS